Nightingales Home Health Services announces foray into Chennai

IMT News Desk
IMT News Desk
· 3 min read
Everstone, Everlife agreement

Nightingales Home Health Services, a Medwell Ventures company, announced its entry into Chennai. After successfully establishing a deep presence in Bengaluru, Mumbai, Pune and Hyderabad markets, Nightingales has established its first branch in the centrally located area of Adyar in Chennai. A multi disciplinary and experienced  team will provide comprehensive healthcare services at home including visits by doctors, nurses, physiotherapists, respiratory therapists and wound care therapists. Nightingales has established specialised protocols for management of patients with strokes, COPD, Congestive heart failure, diabetic wounds and musculoskeletal issues at their home.

Nightingales has a 22 year history in home health in Bangalore and since its acquisition by Medwell Ventures the company has transformed its services and has been on rapid expansion across key metros in the country. Vishal Bali, Co-founder & Chairman, Medwell Ventures said, “India is going through a transformation in its healthcare delivery ecosystem and speciality led home healthcare services with a focus on chronic diseases will play a key role in this transformation. Heart diseases, COPD, Strokes, Cancers and Diabetes are 60% cause of mortality in the country. Non Communicable Disease’s (NCD’s) scale to become chronic diseases and currently account for 40% of all hospital stays and 35% of OPD visits. Our model of home healthcare through Nightingales aims to reduce recurrent hospitalisation of patients with chronic diseases by devising personalised care plans for their management at home. NCD’s and neurohealth issues will cost India $4.58 trillion by 2030 and will cause huge health affordability issues. ”

Nightingales currently provides deep coverage through its network of 16 branches across cities. Some of its branches also provide on site physiotherapy services in conjuction with home physiotherapy to provide patients with the continnum of care. Nightingales sets up operations in Chennai at a time where Tamil Nadu has the highest death rate due to lifestyle diseases such as Diabetes and Kidney Disease.

“Chronic diseases are a key healthcare issue in Chennai with a high re-hospitalisation rate. We are bringing to Chennai our extensive experience of home based care protocols and a well qualified clinical, paraclinical and professional management team.  Our Adyar branch will cover 3.2-3.5 million people and subsequent branches will come up in other parts of Chennai. With more than 60% of hospital beds currently present in central Chennai we see post hospitalisation care as an integral offering from Nightingales”, said Narasimha Jayakumar , CEO, Nightingales.

The Nightingales Home Healthcare business has grown from a single branch in Bengaluru in 2014 to 16 branches across 5 cities with a full-time team of over 1,000 medical, paramedical, and healthcare professionals. Nightingales provides over 25000 home health services in a month across its spectrum of care plans and currently has more than 500 post stroke patients under its care delivery. Nightingales also provides an innovative home dentistry service for the elderly and has served thousands of patients across 4 cities.

Commenting on the Chennai launch, Narasimha Jayakumar, CEO, Nightingales also said, “As a technology-based home healthcare company we see our services expand to more than 10 cities in India with multiple branches in each city. Our model of home healthcare is highly differentiated by its clinical focus and we will continue to expand our portfolio of services based on patient centric needs.”

In May 2015, Eight Roads Ventures (Formally known as Fidelity Growth Partners) led $10 million in Series A round in Medwell Ventures followed by a series B-round $ 21mn in 2017 by Mahindra Partners. The company has overall raised about $35 million across its seed, series A, and series B rounds.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk